Top 5 Oil Service Stocks To Invest In Right Now

There is a lot of buzz over recent energy activity in Sub-Saharan Africa. With Anadarko Petroleum (NYSE: APC  ) and Eni (NYSE: E  ) making large gas finds off the coast of Mozambique, several majors are now looking to get in the game as well. BP plans to spend $540 million over the next five years to develop a part of this gas field that could hold well over 100 trillion cubic feet.�

Better drilling technology and relative political stability in the region have allowed several companies to start investing money in the region, and if some of these plays hit paydirt, some companies could be in for big paydays. In this video, Fool.com contributor Tyler Crowe talks with Aimee Duffy about some of the hot energy plays on the African continent and what we should expect from this region in the years to come. �

With more than 94% of its capital investments coming in the international markets for 2013, National Oilwell Varco is positioning itself to be the leader in oil services around the world. To help determine whether it could be a good fit for your portfolio, you're invited to check out The Motley Fool's premium research report featuring in-depth analysis on whether NOV is a buy today. For instant access to this valuable investor's resource, simply click here now to claim your copy.

Top 5 Asian Stocks To Watch For 2015: Value Line Inc (VALU)

Value Line, Inc., incorporated on October 29, 1982, is engaged in producing investment periodicals and related publications and making available copyright data, including certain Ranking System and other information, to third parties under written agreements for use in third-party managed and marketed investment products. The Company operates in two segments: investment periodicals and related publications. During the fiscal year ended March 31, 2013 (fiscal 2013), the Company�� Wholly-owned operating subsidiaries include Value Line Publishing LLC, Vanderbilt Advertising Agency, Compupower Corporation (CPWR) and Value Line Distribution Center (VLDC). The Company markets under brands including Value Line, the Value Line Logo, The Value Line Investment Survey and The Most Trusted Name in Investment Research.

Investment Related Periodicals and Publications

The investment periodicals and related publications offered by Value Line Publishing LLC (VLP) covers a spectrum of investments, including stocks, mutual funds, options and convertible securities. The services generally fall into four categories include Comprehensive reference periodical publications; Targeted, niche periodical newsletters, and Current and historical financial databases. The services (The Value Line Investment Survey, The Value Line Investment Survey - Small and Mid-Cap, The Value Line 600, and The Value Line Fund Advisor Plus) provide both statistical and text coverage of a number of investment securities, with a focus placed on Value Line's research, analysis and statistical ranks. The Value Line Investment Survey is the Company's premier service, published each week and covering approximately 1,700 stocks.

The newsletters (The Value Line Special Situations Service, The Value Line Fund Advisor, The Value Line Convertibles Survey and The Value Line Options Survey) provide information on securities. The Company offers online versions of its products at the Company's Website, www.valueline.com. T! he Value Line Investment Survey is an investment periodical research product providing both timely articles on economic, financial and investment matters and analysis and ranks for equity securities. The Value Line Investment Survey is an investment periodical research product providing both timely articles on economic, financial and investment matters and analysis and ranks for equity securities. The Value Line Investment Survey - Small and Mid-Cap is an investment research product that provides short descriptions of and data for approximately 1,800 small and medium-capitalization stocks.

Value Line Investment Analyzer is a menu-driven software program with filtering, ranking, reporting and graphing capabilities utilizing over 350 data fields for range of industries and indices and for the approximately 1,700 stocks covered in VLP's publication, The Value Line Investment Survey. Value Line Investment Analyzer allows subscribers to apply more than 60 charting and graphing variables for comparative research. Value Line Mutual Fund Survey for Windows is a monthly CD-ROM or Internet product with weekly Internet updates. The program features powerful sorting and filtering analysis tools. It includes features, such as style attribution analysis, a portfolio stress tester, portfolio rebalancing, correlation of fund returns and hypothetical assets. For the Company's institutional customers, Value Line offers both current and historical data for equities, mutual funds, exchange traded funds (ETFs), and convertibles.

Value Line's Fundamental DataFile I contains fundamental data (both current and historical) on approximately 6,400 publicly traded companies that follow United States generally accepted accounting principles (GAAP). Estimates and Projections DataFile offering contains the estimates from Value Line analysts on approximately 1,700 companies. Data includes earnings, sales, cash flow, book value, margin, and other popular fields. Projections are for the future one year, three ! year and ! five year periods. The Value Line Mutual Fund DataFile, covers more than 20,000 mutual funds with up to 20 years of historical data with more than 200 data fields. The Mutual Fund DataFile provides monthly pricing, basic fund information, weekly performance data, sector weights, and many other popular mutual fund data fields. The Value Line Research Center provides on-line access to select Company investment research products covering stocks, mutual funds, options and convertible securities, as well as special situation stocks.

Copyright Data Fees Programs

The Company has copyright data, which include certain ranking system information and other information used in third party products, such as unit investment trusts, variable annuities, managed accounts and exchange traded funds, which it distributes under copyright data agreements. The Company�� primary copyright data products have been structured as unit investment trusts, ETFs, annuity products and other types of managed products.

Investment Management Services

The Company through its wholly-owned subsidiary ESI, was the distributor for the Value Line Funds. State Street Bank is the custodian of the assets of the Value Line Funds and provides them with fund accounting and administrative services. Shareholder services for the Value Line Funds are provided by Boston Financial Data Services, an affiliate of State Street Bank.

Advisors' Opinion:

• [By Geoff Gannon]

  If a company has an at risk business, it can allocate capital to other areas. Many successful companies no longer engage in the business they started in. If American Express (AXP) stayed in its original business, it wouldn't be around today. The same is true of IBM, MMM, and BRK.B. Some companies choose to pay large dividends or buy back stock while the business is failing rather than allocating capital into a different industry. Let's look at Value Line (VALU). Over the last 10 years, Value Line has paid out about 85% of the company's current market cap. It's a dying business. It had a decision to make. It could allocate capital to new areas inside the corporation, it could pay dividends, or it could buyback stock. It chose to pay dividends.

• [By Geoff Gannon] be cheap enough. It was an issue of Warren Buffett being confident enough to invest in IBM.

  By the way, let�� look at IBM�� past record:

  10-Year Average Return on Assets: 10.3%

  10-Year Annual Sales Growth: 2.8%

  10-Year Annual Asset Growth: 1.9%

  As you can see, IBM isn�� much of a growth company. But that doesn�� mean the shares can�� be growth shares. IBM has improved margins and bought back stock. That has led to a 20% annual increase in earnings per share compared to just a 3% annual increase in total revenue.

  So can we answer the question of why Warren Buffett is interested in companies like IBM and Norfolk Southern (NSC) rather than Hewlett-Packard and Value Line?

  Well, Value Line is obviously too small an investment for Buffett. But we��e using it as a stand in for all the publishers Buffett once loved but now shuns.

  Buffett is a return on investment investor. He isn�� exactly a growth investor or a value investor ��if by growth we mean total revenue growth and if by value we mean the company�� value as of today.

  Buffett wants to compound his money at the fastest rate possible. So he looks at how much of the company�� sales, assets, etc. he is getting. Basically, he looks at a price ratio. And then he looks into the company�� return on its own sales, assets, etc. When you take those two numbers together you get something very close to a rate of return.

  The last part you need to consider is the change in assets versus the change in sales (and earnings). Does the company need to grow assets faster than earnings?

  Or ��like See�� Candy ��can it grow sales a little faster than assets?

  Let�� take a look at Norfolk Southern as a good example of the kind of railroad Buffett would own ��if he didn�� own all of Burlington Northern.

  Norfolk Southern

  10-Year Average Return on Assets: 4.9%

  10-Year Annual Sales Growth: 6.0%

  10-Year Annual Asset Gr

Top 5 Oil Service Stocks To Invest In Right Now: Obagi Medical Products Inc.(OMPI)

Obagi Medical Products, Inc., a specialty pharmaceutical company, develops, markets, and sells topical aesthetic and therapeutic prescription skin care systems. It offers Obagi Nu-Derm System, including prescription and OTC drugs that are used for the treatment of fine lines, wrinkles, acne, photo damage, hyperpigmentation, melasma, laxity, and skin sallowness; Obagi Condition and Enhance Systems that are used before and after surgical and non-surgical cosmetic procedures; Obagi-C Rx System comprises Vitamin C with 4% hydroquinone system to treat skin conditions resulting from sun damage and the oxidative damage of free radicals; and Professional-C products consisting of Vitamin C serums for the treatment of antioxidant protection, fine lines, wrinkles, and hyperpigmentation. The company also provides ELASTIderm Eye and D�olletage, which increases the elasticity and skin tone of eyes, face, neckline, and chest; ELASTILash Eyelash Solution that enhances the appearance of thickness and fullness of eyelashes; CLENZIderm M.D. Systems and Tretinoin for treating acne; and Obagi Rosaclear System used for the treatment of rosacea. In addition, it offers Refissa and Blue Peel RADIANCE used for the treatment of fine facial lines, hyperpigmentation, and tactile roughness; Metronidazole used for the treatment of rosacea; Obagi Blue Peel Essential Kit used for the treatment of fine lines, wrinkles, and hyperpigmentation. Further, the company licenses non-prescription product concepts under the Obagi trademark to a Japanese-based pharmaceutical company for sale through consumer distribution channels in Japan. Obagi Medical Products, Inc. sells its products through sales force and distribution partners in the United States, North and Central America, Europe, the Middle East, and Asia to dermatologists, plastic surgeons, and other physicians that are focused on aesthetic and therapeutic skin care. The company was founded in 1988 and is headquartered in Lon g Beach, California.

Advisors' Opinion:

• [By David Williamson]

  Though many excited traders had hoped to see the bidding war continue between Valeant Pharmaceuticals (NYSE: VRX  ) and Merz over Obagi Medical Products (NASDAQ: OMPI  ) and a subsequent run-up in the stock price of the smaller dermatological products maker, Merz has now walked away from the table, leaving the highly acquisitive Valeant the victor. In this video, Motley Fool health care analyst David Williamson gives us some background on these companies and tells us how Valeant plans to profit from the deal, and describes for investors why this is a win both for Obagi and for Valeant.

• [By Keith Speights]

  "Bidness" is good
  Last week, Obagi Medical Products (NASDAQ: OMPI  ) made our list of humongous performers after Valeant Pharmaceuticals� (NYSE: VRX  ) announced a $344 million bid for the company. This week saw a bidding frenzy, with Obagi shares jumping another 29%.

Top 5 Oil Service Stocks To Invest In Right Now: Nature's Sunshine Products Inc.(NATR)

Nature?s Sunshine Products, Inc., a natural health and wellness company, together with its subsidiaries, primarily engages in the manufacture and direct sale of nutritional and personal care products worldwide. The company offers herbal products in the form of capsules or tablets; and single herbs and herb combinations in the form of liquid herbs and extracts under ALJ, Cardio Assurance, Blood Pressurex, LBS II, CleanStart, Mistica, Liquid Chlorophyll, Noni Plus, and Core Greens brands. It also provides vitamins and mineral supplements, including a line containing natural antioxidants in the form of chewable or non-chewable tablets under EverFlex, Super Supplemental, Vitamin B Complex, Probiotic Eleven, Food Enzyme, ProArgi-9 Plus, SyneMax, and Vitazone brands; and personal care products, such as oils and lotions, aloe vera gels, herbal shampoos, herbal skin treatments, toothpastes, and skin cleansers under Tei-Fu, Pau-D Arco, EverFlex, Pro-G Yam, Hydrating Toner, 5 in 1 Shampoo, Repair Complex, and Bright Renewal Serum brands. In addition, the company offers various other products, such as homeopathic products, powders, sales aids, and other miscellaneous products under Lavender Oil, Tei-Fu Oil, Peppermint Oil, Flower Essences, and Massage Oil brands. It sells its products to a sales force of independent distributors and managers, who use the products themselves or resell them to other independent distributors or consumers. Nature?s Sunshine Products, Inc. was founded in 1972 and is based in Provo, Utah.

Advisors' Opinion:

• [By Rick Aristotle Munarriz]

  Alamy You can never know in advance all the news that will move the market in a given week, but some things you can see coming. From a direct marketer of wellness supplements stepping up with healthy financials (we hope) to Olive Garden's parent checking in with a report on the dreary state of casual dining, here are some of the things that will help shape the week that lies ahead on Wall Street. Monday -- Human Nature Nature's Sunshine Products (NATR) distributes natural wellness products through its growing direct sales force of more than 340,000 reps worldwide, and it also happens to be kicking off the new trading week with its latest financials. Analysts expect to see healthy bottom-line growth in Monday morning's quarterly report. They predict a profit of $0.35 a share, well ahead of the $0.28 a share it rang up a year earlier. The rub is that Nature's Sunshine has come up short against Wall Street profit targets in three of the past four quarters. Tuesday -- Photoshop These Financials Adobe Systems (ADBE) reports on Tuesday. The desktop publishing software giant behind Photoshop, Flash, and PDF authoring platform Acrobat has seen better days. The market's bracing for a dip in revenue and profitability in its latest quarter. That probably isn't much of a surprise. There are now free or nearly free Web-based alternatives to many of Adobe's products. The alternatives may not have as many features, but they're more than enough for casual users. Adobe is going to need new products to get back on the growth track. Wednesday -- New Home Sales Brewing One of the economy's biggest turnaround stories is the residential real estate revival. Folks are buying houses again and they're willing to pay more for them, which is making developers a lot of money. After all, their component costs aren't rising at the same clip as home prices. We'll get a great snapshot of the industry this week. KB Home (KBH) reports on Wednesday, and Lennar (LEN) follows a day lat

Top 5 Oil Service Stocks To Invest In Right Now: C.R. Bard Inc. (BCR)

C. R. Bard, Inc., together with its subsidiaries, engages in the design, manufacture, packaging, distribution, and sale of medical, surgical, diagnostic, and patient care devices worldwide. It offers vascular, urology, oncology, and surgical specialty products. The company?s vascular products include percutaneous transluminal angioplasty catheters, chronic total occlusions catheters, guidewires, introducers, and accessories; peripheral vascular stents and stent grafts, vena cava filters, and biopsy devices; electrophysiology products, such as electrophysiology laboratory systems and diagnostic, therapeutic, and temporary pacing electrode catheters; and fabrics, meshes, and implantable vascular grafts. Its urology products comprise infection control Foley catheters to reduce the rate of urinary tract infections; surgical slings to treat stress urinary incontinence; fecal incontinence products; natural and synthetic devices to treat pelvic floor and vaginal prolapse; brachyt herapy services, devices, and radioactive seeds to treat prostate cancer; intermittent urinary drainage catheters, and urine monitoring and collection systems; ureteral stents; specialty devices for ureteroscopic procedures and stone removal; and catheter stabilization devices. The company?s oncology products consist of specialty vascular access catheters and ports, vascular access ultrasound devices, dialysis access catheters, and enteral feeding devices to treat and manage various cancers, and other diseases and disorders. Its surgical specialty products include implanted patches and fixation systems for hernia and other soft tissue repairs; irrigation devices for orthopedic, laparoscopic, and gynecological procedures; and products for topical hemostasis. C. R. Bard sells its products directly and through distributors to hospitals, individual health care professionals, extended care facilities, and alternate site facilities. The company was founded in 1907 and is based in Murray Hill, New Jersey.

Advisors' Opinion:

• [By Brian Pacampara]

  Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, medical device company C.R. Bard (NYSE: BCR  ) has earned a coveted five-star ranking.